Sensei Biotherapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sensei Biotherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sensei Biotherapeutics Inc Strategy Report
- Understand Sensei Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sensei Biotherapeutics Inc (Sensei) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes innovative immuno-oncology medicines. The company offering products include SNS-101, SNS-102 and SNS-103. The company's patented and proprietary technology platform SPIRIT, creates novel therapies that target neoantigens or altered self-antigens. Sensei is advancing a new class of immuno-oncology therapies to stimulate the immune system to recognize cancer-specific antigens and attack cancer cells. It develops and commercializes an integrated set of diagnostics and therapeutics for cancer. Sensei is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
1405 Research Blvd, Suite 125, Rockville, Maryland, 20850
Website
www.senseibio.com
Telephone
1 240 2438000
No of Employees
27
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SNSE (NASD)
EPS
XYZ
Net Income (2022)
XYZ
29.8%
(2022 vs 2021)
Market Cap*
$25.6M
* As of and is in US$
Sensei Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| SNS-101: Solid Tumors |
| SNS-102: Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company implemented a stockholder rights agreement to safeguard stockholder interests and optimize value for all stockholders. |
| 2023 | Contracts/Agreements | In February, the company signed a cooperative research and development agreement with the National Cancer Institute to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody. |
| 2023 | Contracts/Agreements | In January, the company entered into a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo (cemiplimab). |
Competitor Comparison
| Key Parameters | Sensei Biotherapeutics Inc | Merck & Co Inc | AstraZeneca Plc | Bristol-Myers Squibb Co | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
| City | Rockville | Kenilworth | Cambridge | Princeton | Foster City |
| State/Province | Maryland | New Jersey | England | New Jersey | California |
| No. of Employees | 27 | 72,000 | 89,900 | 34,100 | 18,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Ringo | Chairman | Executive Board | 2022 | 77 |
| John K. Celebi | Chief Executive Officer; Director; President | Executive Board | 2018 | 51 |
| Edward Van Der Horst | Chief Scientific Officer | Senior Management | 2022 | 50 |
| Christopher Gerry | Vice President; General Counsel | Senior Management | - | - |
| Stephanie Krebs | Chief Business Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer